Genetic Regulators of Human Melanocytic Neoplasia
人类黑素细胞肿瘤的遗传调节因子
基本信息
- 批准号:7217530
- 负责人:
- 金额:$ 1.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAntibodiesApoptosisArchitectureBRAF geneBiochemical GeneticsBlocking AntibodiesCDK4 geneCadherinsCarcinogensCell Adhesion MoleculesCell Proliferation RegulationCellsClinicalDisruptionDominant-Negative MutationE-CadherinGenesGeneticGoalsGrowthHumanImmuneInvasiveLaboratoriesMaintenanceMalignant - descriptorMalignant NeoplasmsMedicalMelanocytic NeoplasmMelanoma CellMitogen-Activated Protein KinasesModelingMusMutationN-CadherinNatural regenerationNeoplasm MetastasisNeoplasmsOncogenicPathogenesisPathway interactionsProtein IsoformsProtein OverexpressionPusRegulationRepressionRoleSCID MiceSamplingSignal TransductionSkinSkin CancerStagingStimulusTP53 geneTherapeutic InterventionTumor Cell Invasionbasecell motilitygene inductiongenetic elementgenetic regulatory proteinhuman tissuein vivoinsightkeratinocytemelanocytemelanomamouse modelmutantprogramsreconstitutionresponseskin xenografttumortumorigenesistumorigenic
项目摘要
DESCRIPTION (provided by applicant):
Genetic Regulators of Human Melanocytic Neoplasia: Malignant melanoma is the most common fatal skin cancer. Human tumor samples and mouse models have provided insight into pathways that are altered in melanoma, including activation of Ras, blockade of Rb and p53, as well as change n the adhesion molecule repertoire. However, the medical relevance of murine models of melanoma is limited by major differences between mouse and human skin architecture and by the greater ease of transformation of murine cells. No study has yet addressed the necessity of specific genetic elements in the promotion or maintenance of melanoma in human tissue. Our laboratory's recent finding that defined genetic elements (namely activated Ras, dominant-negative p53, activated cdk4) can act in concert to recapitulate invasive human rnelanocytic neoplasia in human skin regenerated on immune-deficient mice allows for studies of the mechanistic basis for human rnelanocytic carcinogen sis. This proposal aims to use this model to determine the role of specific regulatory proteins and adhesion molecules in the promotion of human rnelanocytic neoplasia. First, the role of the Ras downstream regulator B-Raf will be examined by evaluating the effects of a) activated B-Raf mutants and b) the blockade of downstream Ras effectors on the induction of invasive rnelanocytic neoplasia in primary melanocytes in reconstituted human skin. Second we will address the role of the order of genetic alterations in tumor induction using reciprocal temporal induction of dominant-negative p53 and activated Ras. Additionally, we will determine if p53 disruption is necessary/ to sustain rnelanocytic neoplasia. Third, we will use both genetic and biochemical means to modify E- and N-cadheriri activity, to determine their role in tumor invasion. These studies will provide greater understanding of the roles of Ras, p53, and cadherins in the pathogenesis of rnelanocytic tumors, and may provide targets for therapeutic intervention in human melanoma.
描述(由申请人提供):
人黑色素细胞肿瘤的遗传调节剂:恶性黑色素瘤是最常见的致命皮肤癌。人类肿瘤样品和小鼠模型已提供了对黑色素瘤改变的途径的见解,包括RAS的激活,RB和p53的封锁,以及改变粘附分子库。然而,黑色素瘤鼠模型的医学相关性受小鼠和人皮肤结构之间的主要差异以及鼠细胞转化的易于变化的限制。尚无研究涉及在人体组织中促进或维持黑色素瘤中特定遗传因素的必要性。我们的实验室最近的发现,即定义的遗传元件(即激活的RA,主导的阴性p53,激活的CDK4)可以协同起作用,以概括人类皮肤中人类皮肤上的侵袭性人类r型肿瘤性肿瘤性肿瘤,从而可以在免疫缺陷型中重新生成,从而可以研究人类rnelanoanocytic carccycy carccycy carccyin carcciyen carccyin siss siss sis。该建议旨在使用该模型来确定特定调节蛋白和粘附分子在促进人雷诺型肿瘤中的作用。首先,将通过评估a)激活的B-RAF突变体的作用来研究RAS下游调节剂B-RAF的作用,b)下游RAS效应子对诱导侵入性肾素瘤的封锁,在重构人类皮肤中诱导侵袭性的r型肿瘤性肿瘤。其次,我们将利用互惠的p53和活化的Ras来解决遗传改变在肿瘤诱导中的作用。此外,我们将确定p53的破坏是否需要/维持rne型肿瘤。第三,我们将同时使用遗传和生化手段来修饰E-和N-钙卫纤维活性,以确定它们在肿瘤侵袭中的作用。这些研究将对RAS,p53和钙粘蛋白在rneanocyty肿瘤发病机理中的作用有更深入的了解,并可能为人类黑色素瘤的治疗干预提供靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AMY E ADAMS其他文献
AMY E ADAMS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AMY E ADAMS', 18)}}的其他基金
Genetic Regulators of Human Melanocytic Neoplasia
人类黑素细胞肿瘤的遗传调节因子
- 批准号:
6968973 - 财政年份:2005
- 资助金额:
$ 1.98万 - 项目类别:
Genetic Regulators of Human Melanocytic Neoplasia
人类黑素细胞肿瘤的遗传调节因子
- 批准号:
7090072 - 财政年份:2005
- 资助金额:
$ 1.98万 - 项目类别:
相似国自然基金
YTHDF3调控CXCL13表达影响黑色素瘤免疫微环境及PD-1抗体疗效的机制
- 批准号:82303866
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
AID介导抗体重链非编码区重组调控质膜BCR密度并影响记忆B细胞命运决定的研究
- 批准号:32370948
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
P29单克隆抗体的3-羟基丁酰化修饰对其稳定性影响及提升抗泡型包虫病作用的研究
- 批准号:82360402
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
- 批准号:82304205
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
心衰患者中单克隆β1-肾上腺素受体自身抗体的筛选及其对受体构象影响的研究
- 批准号:32271156
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
相似海外基金
Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
- 批准号:
10752046 - 财政年份:2024
- 资助金额:
$ 1.98万 - 项目类别:
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
选择性剪接的细胞表面蛋白作为白血病发生的驱动因素和免疫治疗的靶点
- 批准号:
10648346 - 财政年份:2023
- 资助金额:
$ 1.98万 - 项目类别:
Cellular mechanisms for the degeneration and aging of human rotator cuff tears
人类肩袖撕裂变性和衰老的细胞机制
- 批准号:
10648672 - 财政年份:2023
- 资助金额:
$ 1.98万 - 项目类别:
A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis
一流的牛皮癣局部免疫调节疗法
- 批准号:
10820331 - 财政年份:2023
- 资助金额:
$ 1.98万 - 项目类别: